Clinical Presentations of Parvovirus B19 Infection



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2007 Feb 1;75(3):373-376.

  Patient information: See related handout on parvovirus B19, written by the authors of this article.

Although most persons with parvovirus B19 infection are asymptomatic or have mild, nonspecific, cold-like symptoms, several clinical conditions have been linked to the virus. Parvovirus B19 usually infects children and causes the classic “slapped-cheek” rash of erythema infectiosum (fifth disease). The virus is highly infectious and spreads mainly through respiratory droplets. By the time the rash appears, the virus is no longer infectious. The virus also may cause acute or persistent arthropathy and papular, purpuric eruptions on the hands and feet (“gloves and socks” syndrome) in adults. Parvovirus B19 infection can trigger an acute cessation of red blood cell production, causing transient aplastic crisis, chronic red cell aplasia, hydrops fetalis, or congenital anemia. This is even more likely in patients with illnesses that have already shortened the lifespan of erythrocytes (e.g., iron deficiency anemia, human immunodeficiency virus, sickle cell disease, thalassemia, spherocytosis). A clinical diagnosis can be made without laboratory confirmation if erythema infectiosum is present. If laboratory confirmation is needed, serum immunoglobulin M testing is recommended for immunocompetent patients; viral DNA testing is recommended for patients in aplastic crisis and for those who are immunocompromised. Treatment is usually supportive, although some patients may require transfusions or intravenous immune globulin therapy. Most patients recover completely.

Parvovirus B19 infection is common worldwide, and most persons who contract the virus are infected by 15 years of age. Infection is most common in late winter or early spring.1 The virus is transmitted through exposure to infected respiratory droplets or blood products and vertically from mother to fetus.1 Exposure to respiratory droplets is the most common means of transmission. The transmission rate is about 50 percent for those living with infected persons and about 20 to 30 percent for susceptible teachers and day care workers who are exposed to infected children.1 Nosocomial transmission also has been documented.2 The incubation period of the infection ranges from four to 14 days but can last as long as 21 days.1

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation Evidence rating References

Patients with persistent parvovirus B19 infection may benefit from intravenous immune globulin therapy.

C

13

Pregnant women who are diagnosed with parvovirus B19 infection should receive serial ultrasonography (weekly or biweekly) for 10 to 12 weeks.

C

19

Patients presenting with typical erythema infectiosum (fifth disease) do not need laboratory testing to confirm parvovirus B19 infection.

C

1, 3, 7


A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, see page 295 or http://www.aafp.org/afpsort.xml.

SORT: KEY RECOMMENDATIONS FOR PRACTICE

View Table

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation Evidence rating References

Patients with persistent parvovirus B19 infection may benefit from intravenous immune globulin therapy.

C

13

Pregnant women who are diagnosed with parvovirus B19 infection should receive serial ultrasonography (weekly or biweekly) for 10 to 12 weeks.

C

19

Patients presenting with typical erythema infectiosum (fifth disease) do not need laboratory testing to confirm parvovirus B19 infection.

C

1, 3, 7


A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, see page 295 or http://www.aafp.org/afpsort.xml.

Virology

Parvovirus is a small, single-stranded DNA virus. The lack of a lipid envelope makes it resistant to physical inactivation with heat or detergents.3 The virus targets rapidly growing erythroid progenitor cells, which are found in human bone marrow, fetal liver, human umbilical cord, and peripheral blood.4,5 To become infective, the parvovirus attaches to a P antigen receptor. Persons with parvovirus B19 infection are no longer contagious when the rash appears because viremia has cleared by this point. Most symptoms occur secondary to immune complex formation.

Clinical Conditions Associated with Parvovirus B19

Most persons with parvovirus B19 infection are asymptomatic or exhibit mild, nonspecific, cold-like symptoms that are never linked to the virus.6 However, clinical conditions associated with the infection include erythema infectiosum; arthropathy; transient aplastic crisis; chronic red cell aplasia; papular, purpuric eruptions on the hands and feet (“gloves and socks” syndrome); and hydrops fetalis. Conditions postulated to have a link to parvovirus B19 infection include encephalopathy, epilepsy, meningitis, myocarditis, dilated cardiomyopathy, and autoimmune hepatitis.6

ERYTHEMA INFECTIOSUM (FIFTH DISEASE)

Erythema infectiosum is the most recognizable presentation of parvovirus B19 infection. The disease generally affects children four to 10 years of age,7 although a less-pronounced rash can occur in adults. Prodromal symptoms are mild and include fever, coryza, headache, and nausea. The first stage of the rash (Figure 1A8) presents as erythema of the cheeks (“slapped-cheek” rash) with circumoral pallor. After one to four days, the second stage (Figures 1B and 1C8) appears as a maculopapular rash of the extremities and trunk. Central clearing of the rash is possible, giving it a lacy, reticular pattern.3 The second-stage rash usually lasts one to six weeks. The third stage may continue for the next one to three weeks. The rash persists but varies with exposure to heat or sunlight,6 resolving spontaneously with no permanent sequelae.

The rightsholder did not grant rights to reproduce this item in electronic media. For the missing item, see the original print version of this publication.

Figure 1.

ARTHROPATHY

Arthropathy may be a complication of erythema infectiosum or a primary presentation of parvovirus B19 infection. Approximately 8 percent of children infected with the virus have arthralgia. However, arthralgia is more common in adolescents and adults with parvovirus B19 infection, affecting up to 60 percent of these persons. Arthropathy affects women twice as often as men.9

The pattern of arthropathy differs between adults and children. In adults, the pattern is symmetric and polyarticular and usually involves the proximal interphalangeal and meta-carpophalangeal joints. It affects the knees, wrists, and ankles less often. Arthropathy generally resolves within three weeks but can last for months to years, especially in women. In children, the pattern can be symmetric or asymmetric and usually involves the knees (82 percent of patients) and ankles.9 Some patients may test positive for rheumatoid factor and antinuclear antibodies.

There is a significant overlap in symptoms of parvovirus-related arthropathy and those of other diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus). Patients with parvovirus B19 infections do not have articular erosion.3,10

TRANSIENT APLASTIC CRISIS

Persons with decreased erythrocytes caused by conditions such as iron deficiency anemia, human immunodeficiency virus (HIV), sickle cell disease, spherocytosis, or thalassemia are at risk of transient aplastic crisis if infected with parvovirus B19. The virus causes a cessation of erythrocyte production. This can be life threatening, although most patients make a full recovery within two weeks. Multiple blood transfusions may be necessary initially.

The precipitous drop in hemoglobin also may cause congestive heart failure, a cerebrovascular accident, or acute splenic sequestration. White blood cell and platelet counts also may fall.11 Patients are highly contagious during aplastic crisis and should be isolated to prevent transmission of the virus.11

CHRONIC RED CELL APLASIA

Parvovirus B19 infection may persist in immunocompromised persons without antibodies. Rashes and arthropathy do not develop because they occur secondary to antibody complex deposition in the skin and joints.12 Patients present with fatigue and pallor caused by anemia, which can be severe, prolonged, or recurrent. Reticulocytes may be absent and transfusions may be required. If severe anemia continues, intravenous immune globulin treatment may be necessary.13 The rash and arthropathy may develop secondary to the infusion of antibodies and the formation of immune complexes. Cessation of immunosuppressant or antiretroviral treatment may ameliorate symptoms in patients with HIV.12

GLOVES AND SOCKS SYNDROME

Parvovirus B19 has been associated with papular, purpuric gloves and socks syndrome, although a causative relationship has not been proven. The syndrome typically occurs in young adults and presents as symmetric, painful erythema and edema of the feet and hands. The condition gradually progresses to petechiae and purpura and may develop into vesicles and bullae with skin sloughing.14 A hallmark of the syndrome is a sharp demarcation of the rash at the wrists and ankles, although other areas (e.g., cheeks, elbows, knees, inner thighs, glans penis, buttocks, or vulva) may be involved.15 Patients may generally appear well but may experience arthralgia, fever, or both. Symptoms usually resolve within one to three weeks without scarring. Gloves and socks syndrome also has been associated with hepatitis B, cytomegalovirus, Epstein-Barr virus, human herpesvirus 6, measles, cox-sackievirus B, and drug reactions.16

HYDROPS FETALIS

Pregnancy does not alter parvovirus B19 infection in the mother,17 although the fetal liver and heart may become infected. The infant may develop severe anemia, caused by an already shortened red cell lifespan, or may develop myocarditis from direct infection of the heart. The combination of severe anemia and myocarditis can cause congestive heart failure and hydrops fetalis.18 The estimated risk of transplacental infection is 30 percent. Many fetuses are born without symptoms, but there is a 2 to 6 percent risk of fetal loss.1 Second-trimester pregnancies are the most vulnerable because of increased hematopoiesis in the liver. Although the placenta has an abundance of P antigen receptors for the virus, first-trimester pregnancies have the lowest risk because of the fetal inability to produce immunoglobulin M (IgM) and the difficulty of antibody transfer across the placenta.18

If a pregnant woman is exposed to parvovirus B19, acute infection should be confirmed by testing for the presence of IgM antibodies or by seroconversion of IgG antibodies.19 If acute infection is confirmed, serial ultrasonography (weekly or biweekly) should be performed for 10 to 12 weeks after initial infection to prevent hydrops fetalis.19 The risk virtually disappears after 12 weeks. If hydrops occurs, fetal blood sampling and possible transfusion are necessary.19 Routine testing for parvovirus is not indicated in pregnant women.20

Diagnosis

If erythema infectiosum is present, a clinical diagnosis can be made without laboratory testing.1,3,7 If laboratory testing is needed, there are two types of diagnostic tests to confirm parvovirus B19 infection: B19-specific antibody testing and viral DNA testing. Giant pronormoblasts on a peripheral blood smear or in a bone marrow aspirate are suggestive of parvovirus B19 infection but are not diagnostic.21

Serum IgM testing is recommended to diagnose acute viral infection in immunocompetent patients, with 89 percent sensitivity and 99 percent specificity.22 Elevated IgM antibodies will remain detectable for two to three months after acute infection. IgG testing is less useful because it only indicates previous infection and immunity.1 Viral DNA testing is crucial for the diagnosis of parvovirus B19 infection in patients in transient aplastic crisis or in immunocompromised patients with chronic infection. These patients do not test positive for IgM or IgG and remain contagious.11 Polymerase chain reaction (PCR) assays are preferred over less sensitive nucleic acid hybridization assays. The sensitivity and specificity of PCR assays vary widely among laboratories, and, overall, PCR does not appear to be more sensitive than IgM antibody assays for the diagnosis of acute parvovirus infection.

Treatment

Generally, erythema infectiosum is self-limited and does not require treatment. Patients with arthralgia may require nonsteroidal anti-inflammatory drug treatment.6 Patients in transient aplastic crisis may require erythrocyte transfusions while the marrow recovers.12 Chronic red cell aplasia, if severe, may require intravenous immune globulin therapy.13 This treatment may improve anemia symptoms, but it may precipitate a rash or arthropathy. Intravenous immune globulin also has been used in several case reports of severe illness.13 A vaccine has been developed but is not yet available.23

The Authors

JESSICA T. SERVEY, LT COL (SEL), USAF, MC, is director of the Transitional Residency Program and associate director of the Family Medicine Residency Program at the David Grant Medical Center, Travis Air Force Base, Calif. Dr. Servey received her medical degree from the Uniformed Services University of the Health Sciences, Bethesda, Md., and completed a family medicine residency at the Eglin Air Force Base community hospital, Fla.

BRIAN V. REAMY, COL, USAF, MC, is chair of the Family Medicine Department at the Uniformed Services University of the Health Sciences. Dr. Reamy received his medical degree from Georgetown University School of Medicine, Washington, D.C., and completed a family practice residency at the David Grant Medical Center.

JOSHUA HODGE, CAPT, USAF, MC, is director of predoctoral education for the Malcolm Grow Medical Center Family Medicine Residency Program, Andrews Air Force Base, Md. Dr. Hodge received his medical degree from the University of Chicago (Ill.) and completed a family practice residency at the St. Louis University School of Medicine in Belleville, Ill.

Address correspondence to Jessica T. Servey, LT COL (SEL), USAF, MC, 101 Bodin Circle, Family Medicine Clinic, Travis Air Force Base, CA 94535 (e-mail: jessica.servey@travis.af.mil). Reprints are not available from the authors.

Author disclosure: Nothing to disclose.

The opinions and assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the U.S. Air Force Medical Department or the Air Force service at large.

REFERENCES

1. Parvovirus B19 (erythema infectiosum, fifth disease). In: Red Book 2006: Report of the Committee on Infectious Diseases. 27th ed. Washington, D.C.: American Academy of Pediatrics, 2006:484–7.

2. Bell LM, Naides SJ, Stoffman P, Hodinka RL, Plotkin SA. Human parvovirus B19 infection among hospital staff members after contact with infected patients. N Engl J Med. 1989;321:485–91.

3. Young NS, Brown KE. Parvovirus B19. N Engl J Med. 2004;350:586–97.

4. Brown KE, Mori J, Cohen BJ, Field AM. In vitro propagation of parvovirus B19 in primary foetal liver culture. J Gen Virol. 1991;72(pt 3):741–5.

5. Srivastava CH, Zhou S, Munshi NC, Srivastava A. Parvovirus B19 replication in human umbilical cord blood cells. Virology. 1992;189:456–61.

6. Heegaard ED, Brown KE. Human parvovirus B19. Clin Microbiol Rev. 2002;15:485–505.

7. Plummer FA, Hammond GW, Forward K, Sekla L, Thompson LM, Jones SE, et al. An erythema infectiosum–like illness caused by human parvovirus infection. N Engl J Med. 1985;313:74–9.

8. American Academy of Pediatrics. Red Book Online. Accessed at: http://www.aapredbook.org.

9. Nesher G, Moore TL. Human parvovirus infection. Infect Med. 1997;14:638–42.

10. Naides SJ, Scharosch LL, Foto F, Howard EJ. Rheumatologic manifestations of human parvovirus B19 infection in adults. Arthritis Rheum. 1990;33:1297–309.

11. Smith-Whitley K, Zhao H, Hodinka RL, Kwiatkowski J, Cecil R, Cecil T, et al. Epidemiology of human parvovirus B19 in children with sickle cell disease. Blood. 2004;103:422–7.

12. Posfay-Barbe KM, Michaels MG. Parvovirus B19 in organ transplant recipients. Curr Opin Organ Transpl. 2003;8:283–7.

13. Kurtzman G, Frickhofen N, Kimball J, Jenkins DW, Nienhuis AW, Young NS. Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med. 1989;321:519–23.

14. Alfadley A, Aljubran A, Hainau B, Alhokail A. Papularpurpuric “gloves and socks” syndrome in a mother and daughter. J Am Acad Dermatol. 2003;48:941–4.

15. Metry D, Katta R. New and emerging pediatric infections. Dermatol Clin. 2003;21:269–76.

16. Katta R. Parvovirus B19: a review. Dermatol Clin. 2002;20:333–42.

17. Alger LS. Toxoplasmosis and parvovirus B19. Infect Dis Clin North Am. 1997;11:55–75.

18. Morey AL, Keeling JW, Porter HJ, Fleming KA. Clinical and histopathological features of parvovirus B19 infection in the human fetus. Br J Obstet Gynaecol. 1992;99:566–74.

19. American College of Obstetrics and Gynecologists. ACOG practice bulletin. Perinatal viral and parasitic infections. Number 20, September 2000. Int J Gynaecol Obstet. 2002;76:95–107.

20. Institute for Clinical Systems Improvement. Prenatal care, routine. Accessed June 9, 2006, at: http://www.icsi.org/knowledge/detail.asp?catID=29&itemID=191.

21. Cohen BJ, Buckley MM. The prevalence of antibody to human parvovirus B19 in England and Wales. J Med Microbiol. 1988;25:151–3.

22. Doyle S, Kerr S, O'Keeffe G, O'Carroll D, Daly P, Kilty C. Detection of parvovirus B19 IgM by antibody capture enzyme immunoassay: receiver operating characteristic analysis. J Virol Methods. 2000;90:143–52.

23. Ballou WR, Reed JL, Noble W, Young NS, Koenig S. Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1. J Infect Dis. 2003;187:675–8.



Copyright © 2007 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Download PDF
  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in Pubmed

Navigate this Article